MAPK3 and colorectal adenocarcinoma: Suriyo et al. investigated the inhibition of colorectal adenocarcinoma H508 cells with dose-dependent CPF (5–100 μM) treatment and found that the EGFR/ERK1/2 signaling pathway contributes to CPF-induced growth of colorectal adenocarcinoma H508 cells [60].